These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32409832)

  • 1. COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir.
    Pawlotsky JM
    Clin Infect Dis; 2020 Nov; 71(16):2191-2194. PubMed ID: 32409832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).
    Softic L; Brillet R; Berry F; Ahnou N; Nevers Q; Morin-Dewaele M; Hamadat S; Bruscella P; Fourati S; Pawlotsky JM; Ahmed-Belkacem A
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32376613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
    Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
    Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine and COVID-19: Risk or favorable?
    Poulsen NN; von Brunn A; Hornum M; Blomberg Jensen M
    Am J Transplant; 2020 Nov; 20(11):2975-2982. PubMed ID: 32777170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors].
    Tian L; Liu W; Sun L
    Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):605-611. PubMed ID: 32347055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophilin inhibitors restrict Middle East respiratory syndrome coronavirus
    Sauerhering L; Kupke A; Meier L; Dietzel E; Hoppe J; Gruber AD; Gattenloehner S; Witte B; Fink L; Hofmann N; Zimmermann T; Goesmann A; Nist A; Stiewe T; Becker S; Herold S; Peteranderl C
    Eur Respir J; 2020 Nov; 56(5):. PubMed ID: 32616594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances and challenges in the prevention and treatment of COVID-19.
    Han YJ; Ren ZG; Li XX; Yan JL; Ma CY; Wu DD; Ji XY
    Int J Med Sci; 2020; 17(12):1803-1810. PubMed ID: 32714083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection.
    Watashi K
    Curr Opin Investig Drugs; 2010 Feb; 11(2):213-24. PubMed ID: 20112171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV.
    Milewska A; Chi Y; Szczepanski A; Barreto-Duran E; Dabrowska A; Botwina P; Obloza M; Liu K; Liu D; Guo X; Ge Y; Li J; Cui L; Ochman M; Urlik M; Rodziewicz-Motowidlo S; Zhu F; Szczubialka K; Nowakowska M; Pyrc K
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33219167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production.
    Phillips S; Chokshi S; Chatterji U; Riva A; Bobardt M; Williams R; Gallay P; Naoumov NV
    Gastroenterology; 2015 Feb; 148(2):403-14.e7. PubMed ID: 25305505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the Phytochemical Agents against the SARS-CoV and Some of them Selected for Application to COVID-19: A Mini-Review.
    Idrees M; Khan S; Memon NH; Zhang Z
    Curr Pharm Biotechnol; 2021; 22(4):444-450. PubMed ID: 32619167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
    Atzrodt CL; Maknojia I; McCarthy RDP; Oldfield TM; Po J; Ta KTL; Stepp HE; Clements TP
    FEBS J; 2020 Sep; 287(17):3633-3650. PubMed ID: 32446285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19.
    Liu C; von Brunn A; Zhu D
    Med Drug Discov; 2020 Sep; 7():100056. PubMed ID: 32835213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review on Screening Models for Potential Therapeutic Candidates and Targets Against SARS-CoV-2.
    Das M; Kumar M; Jha A; Madhukiran DR; Bharti K; Mondal S; Mishra B
    Curr Drug Targets; 2021; 22(11):1232-1254. PubMed ID: 33371846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
    Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molnupiravir and Its Antiviral Activity Against COVID-19.
    Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
    Front Immunol; 2022; 13():855496. PubMed ID: 35444647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe Acute Respiratory Syndrome Coronavirus 2 and Coronavirus Disease 2019: A Clinical Overview and Primer.
    Knight TE
    Biopreserv Biobank; 2020 Dec; 18(6):492-502. PubMed ID: 32726140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19.
    Anirudhan V; Lee H; Cheng H; Cooper L; Rong L
    J Med Virol; 2021 May; 93(5):2722-2734. PubMed ID: 33475167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.